Back

Effects of SGLT-2 inhibitors on erythropoiesis and the associated cardio-renal benefits in patients with chronic heart failure

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Advances in GLP1-RAs, SGLT2 inhibitors and more Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Ms Sabina Ugovsek

University Medical Centre Ljubljana, Ljubljana (Slovenia)

4 More presentations in this session

Presentation thumbnail
Impact of individual components of quadruple therapy in octagenerian heart failure patients: results from a real life data
Associate Professor I. Colluoglu (Izmir, TR)
Abstract Slides Video
Presentation thumbnail
Dapagliflozin for heart failure with reduced ejection fraction: early experience of treatment adherence and impact on patient-reported outcomes in EVOLUTION HF, a multinational, observational study
Professor J. Cardoso (Porto, PT)
Abstract Slides Video
Presentation thumbnail
Titration of sacubitril/valsartan in acute heart failure
Doctor S. Doi (Kawasaki, JP)
Abstract Slides Video
Presentation thumbnail
The effect of glucagon-like peptide-1 receptor agonists on patients with heart failure with reduced ejection fraction
Doctor Z. Iakobishvili (Tel Aviv, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Advances in GLP1-RAs, SGLT2 inhibitors and more

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Hemoglobin, hematocrit and heart failure: the SGLT2 inhibitor connection
thumbnail
Congress Presentation
Hematological outcomes of SGLT-2 inhibitors in heart failure patients: a systematic review and meta-analysis
thumbnail
Congress Presentation
Incidence of erythrocytosis and thromboembolic risk in patients with heart failure and reduced ejection fraction treated with SGLT2 Inhibitors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources